Meatable raises USD 35 million in its latest funding round
The Netherlands-based food tech company has raised USD 35 million in its latest funding round led by Agronomics. Other investors that participated in the round include Dutch impact fund Invest-NL, as well as existing investors BlueYard, Bridford, MilkyWay, DSM Venturing, and Taavet Hinrikus.
The funds will be used to expand Meatable’s operations and expedite the commercial launch of its cultivated meat offerings. Meatable aims to attain commercial production volumes and cost parity with conventional meat.
Endowus secures USD 35 million in funding to enhance digital wealth management
The Singapore wealth management platform has raised USD 35 million in its latest funding round, which drew support from its existing investors including UBS Next, Singapore’s EDBI, Prosus Ventures, Lightspeed Venture Partners, and Singtel Innov8. The round also saw participation from new investors comprising Citi Ventures, MUFG Innovation Partners, Endowus employees, as well as “four of Asia’s wealthiest families.”
The funds will be used to further scale Endowus within its core markets of Singapore and Hong Kong. The objective is to bring fee-only, conflict-free wealth management to a broader audience, enhancing penetration and accessibility.
Indonesia’s Goro raises USD 1 million in pre-seed round
The Indonesia-based fractional property marketplace platform has raised USD 1 million in pre-seed funding. The round, led by early-stage venture capital firm Iterative, garnered participation from other investors including XA Network, StashAway’s angel investing program, and property expert Mike Broomell from Colliers Indonesia.
Goro will use the capital to fuel its expansion plans by expanding its team and strengthening its regional user acquisition strategy. —TechNode Global
Credgenics raises USD 50 million in Series B round
The India-based debt collections SaaS platform has secured USD 50 million in a Series B funding round led by Westbridge Capital, Accel, Tanglin Ventures, Beams Fintech Fund, and other investors.
This has bumped Credgenics’ valuation to USD 340 million, and the company plans to use the funds for strategic initiatives including product innovation, market expansion, and to penetrate into other segments of the banking, financial services, and insurance (BFSI) industry.
Neurophth Therapeutics raises RMB 700 million in Series C+ round
The Chinese ophthalmic technology company has concluded a Series C+ funding round, securing RMB 700 million (USD 97.6 million) from various investors. The capital raised will be allocated to finance the clinical trials of Neurophth’s gene therapy products. Additionally, it will be used to enhance the company’s R&D capabilities and expand its gene therapy product pipeline. —36Kr
Xbotspace secures significant Series A funding to propel technological innovation
The Shanghai-based generative artificial intelligence middleware company has concluded a Series A funding round, raising a nine-figure RMB investment. Participating investors in this round include IDG Capital, New Alliance Capital, and Atom Capital.
Xbotspace will use the funds to advance its technology R&D, foster product innovation, and implement cutting-edge applications. —36Kr
Fullcryo raises RMB 800 million in Series C round
The China-based cryogenic equipment producer has raised RMB 800 million (USD 111.6 million) in a Series C funding round co-led by the Mixed Reform Fund and CCB Investment. Yuexiu Fund, China Industrial International Trust, Cascam, and Casstar also participated in the round. —36Kr
Mogic AI secures Series A funding to boost AI-based marketing capabilities
The Chinese AI-based marketing company has secured an eight-figure USD investment in a Series A funding round led by Cathay Capital, with existing investors TrueFund and Zoo Capital also participating.
The funds will mainly be used for technology investments in the field of AI-powered video marketing, including R&D on algorithms and models to further enhance the company’s product capabilities. —36Kr
Ruishi Health secures nine-figure RMB investment in Series A+ round
The Chinese health technology company has completed a nine-figure RMB investment in a Series A+ funding round led by Sinovation Ventures, with participation from Botanee Group as well as existing investors Yaojin Capital and BlueRun Ventures. —36Kr
Spatomics secures eight-figure RMB angel investment
Chinese spatial omics company Spatomics has completed an angel funding round, securing an eight-figure RMB investment from K2 Venture Partners, Shangshi Capital, and Chang’an Capital. K2 Venture Partners led the round. —36Kr
Taiyi Chuanxin raises eight-figure RMB investment in Pre-Series A round
The Shenzhen-based technology company has raised an eight-figure RMB investment after completing its Pre-Series A funding round, backed by Jorde Investment, Tianyu Culture Group, and other investors. The funds will allow Taiyi Chuanxin to enhance its technology capabilities and offer more efficient and secure solutions to its customers. —36Kr
Leilong Technology secures eight-figure RMB investment in Series B round
The Chinese industrial digital technology platform has secured an eight-figure RMB investment in a Series B funding round, led by a CICC Capital-managed fund. The funds will be used to advance the company’s core digital technology platform through R&D initiatives. —36Kr
ULS Robotics concludes Series A round to advance exoskeleton technology development
The Chinese exoskeleton technology company has concluded its Series A funding round, with Guoyi Capital serving as the exclusive investor. The funds will be used to enhance its core exoskeleton product technology and accelerate the development of new products. —36Kr
Disprz and Dotbio led yesterday’s headlines:
- Disprz, an India-based enterprise software-as-a-service learning and skilling platform, raised USD 30 million in a Series C funding round led by Lumos Capital Group and 360 ONE Asset (IIFL). The funding will drive Disprz’s product development, expand its presence in Southeast Asia, India, and the Middle East, and facilitate its entry into the US market.
- DotBio, a Singapore-based biopharmaceutical company, secured USD 5.6 million in a pre-Series A funding round led by Proxima Ventures and Gaorong Capital. DotBio will use the funds for preclinical studies on antibody therapies, chemical processes, manufacturing, and to enhance and automate its proprietary DotBody platform.
If there are any news or updates you’d like us to feature, get in touch with us at: [email protected].